| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Medicine |

and Increases High-Density Lipoprotein Biogenesis Independent of
1-Adrenoceptor Blockade
From the Biochemistry Department (N.I., S.A.-D., N.T., S.Y.), Nagoya City University Graduate School of Medical Sciences; and the First Department of Internal Medicine (M.A., M.K., F.O.), National Defense Medical College, Tokorozawa, Japan.
Correspondence to Dr Shinji Yokoyama, Biochemistry, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan. E-mail syokoyam{at}med.nagoya-cu.ac.jp
ATP-binding cassette transporter A1 (ABCA1) is a rate-limiting factor for high-density lipoprotein (HDL) biogenesis. The ABCA1 gene expression is known to be upregulated by various transcriptional factors. However, negative regulation factors would be better targets for pharmacological modulation of HDL biogenesis. Doxazosin, an
1-adrenoceptor blocker, increased ABCA1 mRNA, its protein, and apolipoprotein A-I–mediated HDL biogenesis in THP-1 macrophages and CHO-K1 cells, independent of
1-adrenoceptor blockade. Analysis of the human ABCA1 promoter indicated that the region between the positions –368 and –147 that contains an activator protein (AP)2-binding site responsible for the effects of doxazosin. Overexpression of AP2
inhibited ABCA1 transcription in a dose-dependent fashion. Mutation in the AP2-binding site caused increase of the basal promoter activity and canceling both the transactivation by doxazosin and the trans-repression by AP2
. Doxazosin had no effect on ABCA1 mRNA level in HepG2 cells, which lack endogenous AP2
, and it reversed the inhibitory effect of AP2
expression in this type of cells. Chromatin immunoprecipitation and gel shift assays revealed that doxazosin reduced specific binding of AP2
to the ABCA1 promoter, as it suppressed phosphorylation of AP2
. Finally, doxazosin increased ABCA1 expression and plasma HDL in mice. We thus concluded that AP2
negatively regulates the ABCA1 gene transcription. Doxazosin inhibits AP2
activity independent of
1-adrenoceptor blockade and increases the ABCA1 expression and HDL biogenesis. AP2
is a potent pharmacological target for the increase of HDL.
Key Words: ABCA1 doxazosin HDL AP2 apoA-I
Related Article:
Circ. Res. 2007 101: 116-118.
This article has been cited by other articles:
![]() |
X Li, K L Monda, H H H Goring, K Haack, S A Cole, V P Diego, L Almasy, S Laston, B V Howard, N M Shara, et al. Genome-wide linkage scan for plasma high density lipoprotein cholesterol, apolipoprotein A-1 and triglyceride variation among American Indian populations: the Strong Heart Family Study J. Med. Genet., July 1, 2009; 46(7): 472 - 479. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Iwamoto, S. Abe-Dohmae, R. Lu, and S. Yokoyama Involvement of Protein Kinase D in Phosphorylation and Increase of DNA Binding of Activator Protein 2{alpha} to Downregulate ATP-Binding Cassette Transporter A1 Arterioscler Thromb Vasc Biol, December 1, 2008; 28(12): 2282 - 2287. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Lu, R. Arakawa, C. Ito-Osumi, N. Iwamoto, and S. Yokoyama ApoA-I Facilitates ABCA1 Recycle/Accumulation to Cell Surface by Inhibiting Its Intracellular Degradation and Increases HDL Generation Arterioscler Thromb Vasc Biol, October 1, 2008; 28(10): 1820 - 1824. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T. Remaley Old Drug, New Tricks: The Unexpected Effect of Doxazosin on High-Density Lipoprotein Circ. Res., July 20, 2007; 101(2): 116 - 118. [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |